Mokoala, Kgomotso M.G.Sathekge, Mike Machaba2025-07-312025-07-312024-11Mokoala, K.M.G. & Sathekge, M.M. 2024, 'Non-FDGhypoxiatracers', Seminars in Nuclear Medicine, vol. 54, no. 6, pp. 827-844. https://doi.org/10.1053/j.semnuclmed.2024.10.0010001-2998 (print)1558-4623 (online)10.1053/j.semnuclmed.2024.10.001http://hdl.handle.net/2263/103721Hypoxia plays a critical role in tumor biology, influencing cancer progression, treatment resistance, and patient prognosis. While 18-Fluorine fluoredeoxyglucose ([18F]F-FDG) PET imaging has been the standard for metabolic assessment, its limitations in accurately depicting hypoxic tumor regions necessitate the exploration of non-FDG hypoxia tracers. This review aims to evaluate emerging non-FDG radiotracers, such as nitroimidazole derivatives, copper-based agents, gallium-based agents and other innovative compounds, highlighting their mechanisms of action, biodistribution, and clinical applications. We will discuss the advantages and challenges associated with hypoxia imaging, as well as recent advancements in imaging techniques that enhance the assessment of tumor hypoxia. By synthesizing current research, this review seeks to provide insights into the potential of non-FDG hypoxia tracers for improving cancer diagnosis, treatment planning, and monitoring, ultimately contributing to more personalized and effective cancer care.en© 2024 The Authors. Published by Elsevier Inc. This is an open access article under the CCBY-NC license.CancerCareHypoxiaRadiotracersArticle